Business Context and Reporting Period
Company: cbdMD, Inc. (NYSE American: YCBD)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three and six months ended March 31, 2025 (Fiscal Q2 2025)
Business Overview: cbdMD operates nationally recognized CBD brands (cbdMD, Paw CBD) and functional mushroom brands (ATRx Labs). The company recently launched the "Oasis" hemp-derived THC beverage line. The company is a smaller reporting company and non-accelerated filer.
Key Financial Metrics
| Metric | Three Months Ended Mar 31, 2025 | Six Months Ended Mar 31, 2025 |
|---|---|---|
| Net Sales | $4,749,426 | $9,862,902 |
| Gross Profit | $2,959,364 (62.3% margin) | $6,359,973 (64.5% margin) |
| Operating Loss | $(485,816) | $(572,088) |
| Net Loss | $(480,757) | $(465,662) |
| Net Loss Attributable to Common Shareholders | $(1,481,257) | $(2,466,663) |
| Cash and Cash Equivalents | $1,765,234 | $1,765,234 (Ending Balance) |
| Working Capital | $(3,679,350) Deficit | $(3,679,350) Deficit |
| Adjusted EBITDA (Non-GAAP) | $(197,986) | $16,831 |
Note: Net Loss attributable to common shareholders includes preferred dividends of $1,000,500 (Q2) and $2,001,001 (YTD).
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 8.5% year-over-year (Q2) and 1.1% year-over-year (YTD). Wholesale sales grew significantly (48.3% Q2 increase) due to a large customer allowance recorded in the prior year that did not recur.
- Expense Reduction: Operating expenses decreased 16.6% year-over-year (Q2) and 20.8% year-over-year (YTD), driven by reduced rent (HQ elimination), lower professional fees, and staff cost reductions.
- Profitability Improvement: Operating loss narrowed significantly from $(1.55M) in Q2 2024 to $(0.49M) in Q2 2025. The company achieved positive Adjusted EBITDA of $16,831 for the six-month period, compared to a loss of $(1.38M) in the prior year.
- Debt Elimination: Convertible notes outstanding at September 30, 2024 ($1.17M fair value) were fully converted to common stock by January 2025, eliminating this liability.
Outlook, Risks, and Unusual Items
- Going Concern Warning: Management states there is "substantial doubt" about the company's ability to continue as a going concern within twelve months due to a working capital deficit and history of losses. Continued operations depend on raising additional capital and improving profitability.
- Subsequent Events (Post-March 31, 2025):
- Preferred Stock Conversion: On May 6, 2025, all Series A Preferred Stock and accrued dividends ($6.7M) were automatically converted to common stock. This action is expected to restore compliance with NYSE American listing standards regarding stockholders' equity.
- Reverse Stock Split: A 1-for-8 reverse stock split was effective May 6, 2025.
- Operational Challenges: Q2 revenue declined sequentially (7%) due to management focus on the preferred stock conversion, marketing team restructuring, and inventory shortages caused by conservative cash management and testing delays.
- Risk Factors: Risks include potential tariffs on imported packaging materials, regulatory changes regarding CBD/hemp, and reliance on third-party suppliers. The company faces delisting risk if it fails to maintain compliance with NYSE American standards by December 5, 2025.
Investor Verification Checklist
- Liquidity Runway: Verify the company's ability to fund operations for the next 12 months given the $3.7M working capital deficit and lack of committed financing.
- Listing Compliance: Confirm that the May 2025 preferred stock conversion has successfully restored stockholders' equity above the $2.0M threshold required by NYSE American.
- Revenue Quality: Assess the sustainability of wholesale revenue growth, noting the Q2 increase was partially due to the absence of a large allowance recorded in the prior year.
- Inventory Levels: Monitor inventory replenishment and product availability following the reported stock shortages in Q2.
- Preferred Dividend Obligation: Confirm that the accrued dividend obligation ($6.7M) has been fully extinguished via the equity conversion and no longer impacts future cash flow.